What is the future of DNA and gene synthesis?Before the covid pandemic, nucleic acids were mostly research tools. Terms like mRNA vaccines (nucleic acids as clinical agents) were relatively unknown. But since then, RNA and DNA have been thrust into the limelight for both the public and investors alike. How will the field evolve?My guest in this episode, Steve Harvey, is working at the forefront of DNA synthesis, so who better to talk us through its evolution and future.Steve is the CEO of Camena Bioscience, where they focus on improving DNA and gene synthesis. This enables biotechnologists to use more accurate and pure starting points, so their results aren’t held back by limited tools.In this episode Steve discusses his career in laboratory research and the biotech space, from manual experiments in a classical wet lab environment through to the evolution of artificial intelligence. He also talks about the quality challenges faced within DNA and gene synthesis, and how Camena Bio addresses those. Steve is just as committed to his people as to his science. He discusses the challenge of scaling a biotech company while keeping that all important dynamic and accountable culture.You’ll hear about:00:56 - Biotechnology and DNA-based therapies07:29 – How AI is changing drug discoveries12:26 – Steve’s biotech experiences 15:09 - DNA sequencing advancements and challenges20:50 – The problems with storing digital information in DNA29:47 – The evolution of DNA synthesis technology 33:56 - Company culture and growth strategies38:57 - Scaling a biotech company with a dynamic cultureFollow Steve:LinkedIn - https://www.linkedin.com/in/steve-harvey-camenabio/ Twitter - https://twitter.com/camenabio Camena Bioscience - https://www.camenabio.com/ Connect with Me:LinkedIn: https://www.linkedin.com/in/markdavison100/ Grant Instruments: https://www.grantinstruments.com/ Grant Instruments on LinkedIn: https://www.linkedin.com/company/grant-instruments-cambridge-ltd/ 

Ver todos los episodios